Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Smoldering Multiple Myeloma × isatuximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 25 Renal Insufficiency 3 Recurrence 3 Neoplasms, Plasma Cell 3 Neoplasms 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Paraproteinemias 2 Neoplasms by Histologic Type 2 Hematologic Diseases 2 Blood Protein Disorders 2 Smoldering Multiple Myeloma 1 Purpura 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm, Residual 1 Nausea 1 Natural Killer/T-cell Lymphoma 1 Monoclonal Gammopathy of Undetermined Significance 1 Macroglossia 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Lymphadenopathy 1 Leukemia, Plasma Cell 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Immunoglobulin Light-chain Amyloidosis 1 Hodgkin Disease 1 Hepatomegaly 1 Hematologic Neoplasms 1 Gastrointestinal Hemorrhage 1 Diarrhea 1

Interventions

Dexamethasone 9 Lenalidomide 8 carfilzomib 4 Calcium Dobesilate 4 daratumumab 3 elotuzumab 2 Denosumab 2 selinexor 1 pomalidomide 1 piperine 1 ixazomib 1 isatuximab 1 ibrutinib 1 iberdomide 1 fludarabine phosphate 1 fludarabine 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 auricularum 1 Simvastatin 1 Nivolumab 1 Metformin 1 Melphalan 1 Leflunomide 1 IPH-2101 1 Gene Expression Profiling 1 Fatty Acids, Omega-3 1 Cyclophosphamide 1 Curcumin 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06762769 2025-08-01

MODIFY

University College, London

Phase 2 Recruiting

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡